{"id":"W3088612260","doi":"10.1016/j.annonc.2020.08.2300","title":"LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; La Cité Médicale; Moncton Hospital; Jewish General Hospital; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier de l’Université de Montréal; Hôtel-Dieu de Québec; Vancouver General Hospital; Princess Margaret Cancer Centre; CancerCare Manitoba; Ottawa Hospital; London Health Sciences Centre","funders":"","keywords":"Medicine; Gemcitabine; Clinical endpoint; Internal medicine; Hazard ratio; Durvalumab; Randomized controlled trial; Oncology; Nab-paclitaxel; Surrogate endpoint; Urology; Cancer; Gastroenterology; Confidence interval; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002118846,0.002285536,0.003950312,0.0007118389,0.0008331374,0.00167181,0.001415269,0.001888198,0.007718979],"category_scores_gemma":[0.00217607,0.0006464943,0.003772783,0.0009394143,0.001451366,0.0009044657,0.0005770502,0.004814434,0.001439453],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003268602,"about_ca_system_score_gemma":0.005148875,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02903142,"about_ca_topic_score_gemma":0.06806856,"domain_scores_codex":[0.9990644,0.0004806453,0.00003445013,0.0001395871,0.0001001502,0.0001807835],"domain_scores_gemma":[0.9989605,0.0002179401,0.0001995164,0.00007950594,0.00007534732,0.0004671487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9625458,0.003514308,0.001438581,0.0007441676,0.002333298,0.00005158251,0.00004431911,0.000627869,0.002121948,0.0003675475,0.005965251,0.02024524],"study_design_scores_gemma":[0.9571836,0.03075555,0.005773675,0.00007807626,0.001831578,0.0000670704,0.00003553796,0.0004600667,0.0002328234,0.0002627881,0.0032853,0.00003387717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9378484,0.02668342,0.0007125019,0.003949701,0.001726912,0.003436846,0.01264927,0.00042892,0.01256398],"genre_scores_gemma":[0.9540726,0.009987182,0.002597593,0.003834644,0.0009345965,0.003785017,0.01467358,0.0001480615,0.009966739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02903142,"threshold_uncertainty_score":0.05772489,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1765211334578372,"score_gpt":0.4227879499531035,"score_spread":0.2462668164952663,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}